Topical treatment with 22-oxacalcitriol (OCT), a new vitamin D analogue, caused severe hypercalcemia with exacerbation of chronic renal failure in a psoriatic patient with diabetic nephropathy; a case report and analysis of the potential for hypercalcemia

Internal Medicine

Volumn 42, Issue 12, 2003, Pages 1202-1205

  Ohigashi, Sawako ^a   Tatsuno, Ichiro ^a   Uchida, Daigaku ^b   Higurashi, Mayumi ^a   Hoshimoto, Saori ^a   Seki, Naoto ^a   Hashimoto, Natoake ^a   Saito, Yasushi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KIMITSU CHUO HOSPITAL   (Japan)

Author keywords

22 oxacalcitriol; Diabetic nephropathy; Hypercalcemia; Psoriasis; Renal failure

Indexed keywords

22 OXACALCITRIOL; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CREATININE; ELCATONIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRATE; URIC ACID; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CASE REPORT; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; HYPERCALCEMIA; HYPERLIPIDEMIA; JAPAN; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PSORIASIS;

EID: 1642463424     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.1202     Document Type: Article

References (21)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46: 1-23, 2002.
2. Georgiou S, Tsambaos D. Hypercalcaemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol. Acta Derm Venereol 79: 86, 1999.
3. Russell S, Young MJ. Hypercalcaemia during treatment of psoriasis with calcipotriol. Br J Dermatol 130: 795-796, 1994.
4. Bourke JF, Berth-Jones J, Hutchinson PE. Hypercalcemia with topical calcipotriol. Brit Med J 306: 1344-1345, 1993.
5. Anonymous. Topical calcipotriol and hypercalcaemia. Lancet 337: 1287-1288, 1991.
6. 3. Kidney Int (suppl) 73: S46-S51, 1999.
7. Nishii Y, Abe J, Mori T, et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. Contrib Nephrol 91: 123-128, 1991.
8. Nishii Y, Okano T. History of the development of new vitamin D analogs: studies on 22-oxacalcitriol (OCT) and 2 beta-(3-hydroxypropoxy)calcitriol (ED-71). Steroids 66: 137-146, 2001.
9. Brown AJ. Therapeutic uses of vitamin D analogues. Am J Kidney Dis 38: S3-S19, 2001.
10. Brown AJ, Ritter CR, Finch JL, et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84: 728-732, 1989.
11. 3 analogue, OCT, on immunomodulatory function of keratinocytes and lymphocytes. Arch Dermatol Res 291: 500-506, 1999.
12. Barker JN, Ashton RE, Marks R, Harris RI, Berth-Jones J. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 141: 274-278, 1999.
13. Anonymous. The report of post-marketing vigilance system to collect information of side effects regarding 22-oxacalcitol in 2002. Maruho Phamaceutical Company, Japan, 2002.
14. Asadullah K, Volk HD, Sterry W. Novel immunotherapies for psoriasis. Trends Immunol 23: 47-53, 2002.
15. Barnetson RS, White AD. The use of corticosteroids in dermatological practice. Med J Aust 156: 428-431, 1992.
16. Tremblay JF, Bissonnette R. Topical agents for the treatment of psoriasis, past, present and future. J Cutan Med Surg 6: 8-11, 2002.
17. Cather J, Menter A. Novel therapies for psoriasis. Am J Clin Dermatol 3: 159-173, 2002.
18. Nagpal S, Lu J, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem 8: 1661-1679, 2001.
19. Lamba S, Lebwohl M. Combination therapy with vitamin D analogues. Br J Dermatol 144: 27-32, 2001.
20. Masuda S, Byford V, Kremer R, et al. In vitro metabolism of the vitamin D analog, 22-oxacalcitriol, using cultured osteosarcoma, hepatoma, and keratinocyte cell lines. J Biol Chem 271: 8700-8708, 1996.
21. Ishigai M, Arai S, Ishitani Y, Kumaki K. In vivo metabolism of the vitamin D analog, 22-oxacalcitriol: evidence for side-chain truncation and 17-hydroxylation. J Steroid Biochem Mol Biol 66: 281-293, 1998.